Current Perspective On the Use of Calcium Channel Blockers to Treat Hypertensive Patients: the Role of Lercanidipine

Abstract

The symposium ‘Current perspective on the use of calcium channel blockers in the treatment of hypertensive patients’, held in Stresa (Italy) on 28th and 29th June 2018 with the participation of the main experts in the field of hypertension from all over the world, reviewed the role of calcium channel blockers in the management of hypertension. Considering the new European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines presented at the last European Society of Hypertension meeting in Barcelona in June 2018, a special attention was focused on lercanidipine. In this article, the main highlights of the symposium were summarized.

Keywords:

• calcium channel blocker
• hypertension
• lercanidipine

Author contributions

G Mancia and K Tsioufis equally contributed to this work.

Financial & competing interests disclosure

K Tsioufis received travel expenses or research grant or honoraria fees from the following: Medtronic, St Jude Medical, Bayer, Novartis, AstraZeneca, Boehringer In, Pfizer, Chiesi, Pharmanel, Sanofi, Vianex, Win-Medica, ELPEN, Recordati and Servier. K Tsioufis is also President of European Society of Hypertension and Past President of Hellenic Society of Cardiology. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Content Ed Net Srl provided editorial support with the helpful assistance of Elisa Sala, PhD Medical Writer; this support was funded by Recordati.

Notes

BP: Blood pressure; CV: Cardiovascular.

Data taken from [1].